LungLife AI, INC Result of AGM (1544L)

TIDMLLAI

RNS Number : 1544L

LungLife AI, INC

11 May 2022

LungLife AI, Inc.

(the "Company" or "LungLife")

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting , held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a poll.

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

 
  Resolution                        Votes for    %     Votes against   %   Votes withheld 
 Resolution 1 ( Common 
  ) 
  TO receive the Annual Report 
  and Accounts of the Company 
  for the year ended 31 December 
  2021 together with the 
  directors' and auditor's 
  reports thereon.                  14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 2 ( Common 
  ) 
  THAT Roy Davis be, and 
  hereby is, re-elected as 
  a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 3 ( Common 
  ) 
  THAT Paul Pagano be, and 
  hereby is, re-elected as 
  a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 4 ( Common 
  ) 
  THAT David Anderson be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 5 ( Common 
  ) 
  THAT Andrew Boteler be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 6 ( Common 
  ) 
  THAT Sara Barrington be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 7 ( Common 
  ) 
  THAT James McCullough be, 
  and hereby is, re-elected 
  as a director of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      --------------- 
 Resolution 8 ( Common 
  ) 
  THAT Crowe LLP be, and 
  hereby is, reappointed 
  as auditor of the Company 
  to hold office until the 
  conclusion of the next 
  Annual General Meeting 
  of the Company.                   14,321,090   100   0               0   0 
                                   -----------  ----  --------------      ---------------

As at 11 May 2022 , there were 25,480,270 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

For further information please contact:

 
LungLife AI, Inc.                                                            www.lunglifeai.com 
Paul Pagano, CEO                                                                Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                   Tel: +44 (0)20 7597 5970 
 & Broker) 
Daniel Adams / Virginia Bull / Cameron 
 MacRitchie 
 
Walbrook PR Limited                       Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings / Phillip                    Mob: 07980 541 893 / 07407 804 654 / 
 Marriage                                                                        0 7867 984 082

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEALSFFFKAEFA

(END) Dow Jones Newswires

May 11, 2022 10:17 ET (14:17 GMT)

Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024